Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.

ABSTRACT:

Background

Hyperuricemia is common in patients with type 2 diabetes mellitus and is known to cause gout. Sodium-glucose cotransporter-2 (SGLT2) inhibitors prevent glucose reabsorption and lower serum uric acid levels.

Objective

To compare the rate of gout between adults prescribed an SGLT2 inhibitor and those prescribed a glucagon-like peptide-1 (GLP1) receptor agonist.

Design

Population-based new-user cohort study.

Setting

A U.S. nationwide commercial insurance database from March 2013 to December 2017.

Patients

Persons with type 2 diabetes newly prescribed an SGLT2 inhibitor were 1:1 propensity score matched to patients newly prescribed a GLP1 agonist. Persons were excluded if they had a history of gout or had received gout-specific treatment previousl

SUBMITTER: Fralick M 

PROVIDER: S-EPMC7217750 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature